Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced a funded partnership with a global large pharmaceutical company to apply Turin, its AI-enabled scientific engine for quantitative systems pharmacology (QSP), within an active therapeutic development program. The collaboration will evaluate how AI-enabled exploration of mechanistic model structures can substantially reduce the time required to build and evaluate QSP models, supporting far broader use within model-informed drug development (MIDD) workflows.
QSP development has traditionally required scientists to make a series of choices about which biological mechanisms to include, how to structure the equations, and which parameters to optimize. These decisions are made with limited ability to test against plausible alternatives, but Turin is designed to change that. The engine enables systematic exploration and evaluation of candidate mechanistic structures against the available evidence in parallel, helping scientists identify the ones that best balance biological complexity, explanatory performance, and practical utility. Turin’s capabilities are further enhanced by the technical collaboration with NVIDIA that was announced in May 2026.
Under this collaboration, the pharmaceutical partner will use Turin within a hosted environment, supported by Simulations Plus scientists, who will provide scientific guidance throughout model evaluation. The approach combines AI-scale computational exploration with expert human scientific judgment, keeping the partner’s scientists directly engaged in every step of the QSP model-building and evaluation process. The partnership is intended to rapidly expand into more therapeutic development programs.
“QSP can provide powerful insight into complex biological systems, but the time and expertise required to build and evaluate these models has historically limited where and when they can be applied,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “Turin is designed to break down that barrier and make QSP practical for a broader range of development decisions. Working alongside a leading pharmaceutical organization allows us to tailor this approach to meaningful challenges in a real-world development setting while continuing to advance the scientific capabilities of the engine.”
Organizations interested in learning more about Turin or exploring potential partnerships may contact Simulations Plus: https://www.simulations-plus.com/contact/
About Simulations Plus, Inc.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com.
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “expect,” “anticipate,” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions, or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements include but are not limited to statements regarding our fiscal year 2026 guidance, revenue growth, anticipated margins and profitability, demand to software and services, the impact of pricing actions, client spending levels, market conditions, the development, capabilities, regulatory acceptance, regulatory compliance and commercialization of AI-enabled and cloud-based solutions, the timing and content of product initiatives discussed at Investor Day, and our ability to execute our long-term strategic vision. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual, and current reports and filed with the U.S. Securities and Exchange Commission. No regulatory authority has endorsed, approved, or validated the Company’s products, platforms, or AI-related approaches.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261008831077/en/
Media gallery
